This infographic illustrates the clinical timeline and treatment progression of a patient with congestive heart failure. The visual combines pharmacological management, serial diagnostic imaging, and biochemical/functional markers. The top section displays a medication timeline featuring intravenous diuretics (furosemide) and vasodilators (nitroglycerin) in the acute phase, followed by long-term oral maintenance with bisoprolol (2.5 mg/day), spironolactone (50 mg/day), and azosemide (60 mg/day). The middle section shows three serial posterior-anterior (PA) chest radiographs from March, June, and September, demonstrating a progressive reduction in cardiomegaly and clearance of pulmonary congestion. The bottom dual-axis line graph tracks B-type natriuretic peptide (BNP) levels (red line) and Ejection Fraction (EF) percentages (blue line). It reveals a sharp peak in BNP (~1200 pg/ml) in April corresponding with acute decompensation, followed by a significant decline to <200 pg/ml. Simultaneously, the EF shows a steady improvement from approximately 25% to 52% by September, correlating with clinical recovery and the effectiveness of the heart failure medication regimen.

Summary : This figure presents a diagnostic algorithm for heart failure (HF) and its classification based on ejection fraction (EF), guiding clinicians through assessment, testing, and classification steps for patients with suspected HF. flowchart: # Nodes : • Diagnostic Algorithm for Patients With Suspected HF (rectangular header) • Assessment (rectangle): Clinical history, Physical examination, ECG, labs • Natriuretic Peptide (rectangle): NT-proBNP >125 pg/mL, BNP ≥35 pg/mL • Transthoracic Echocardiography (rectangle): Additional testing, if necessary • HF Diagnosis Confirmed (rectangle): Determine cause and classify • HFrEF (rectangle): LVEF ≤40% • HFmrEF (rectangle): LVEF 41%-49% • HFpEF (rectangle): LVEF ≥50% • Evaluate for precipitating factors, Initiate treatment (rectangle under all three EF categories) # Connectors : • Top-down arrows connect each step sequentially: Assessment → Natriuretic Peptide → Transthoracic Echocardiography → HF Diagnosis Confirmed. • From "HF Diagnosis Confirmed," three branches lead to HFrEF, HFmrEF, and HFpEF. • Each EF category leads to a shared final step: Evaluate for precipitating factors, Initiate treatment. # Layout : • Vertical flow from top to bottom, with a split into three parallel branches for EF-based classification. • All three EF branches converge to a common final action box. # Analysis : • The algorithm provides a clear, stepwise approach for diagnosing HF, starting with clinical assessment and progressing through biomarker testing and echocardiography. • Classification is based on left ventricular ejection fraction (LVEF): reduced (≤40%), mildly reduced (41%-49%), and preserved (≥50%). • The final step emphasizes evaluating causes and initiating treatment regardless of EF category, supporting a systematic and comprehensive management strategy for HF.

Summary : This figure presents a treatment algorithm flowchart for guideline-directed medical therapy in patients with Heart Failure with Reduced Ejection Fraction (HFrEF) Stage C, outlining medication choices and escalation steps based on patient characteristics. flowchart: # Nodes : • Start (rounded rectangle): "HFrEF Stage C Treatment" • Main therapy (diamond): "ARNI* + evidence-based beta-blocker† + mineralocorticoid antagonist + SGLT inhibitor (Figures 3A-E)" • Four decision nodes (rectangles, left to right): – "For patients with persistent volume overload, NYHA class II-IV" – "For persistently symptomatic African-American patients despite ARNI/beta-blocker/mineralocorticoid antagonist/SGLT inhibitor, NYHA class III-IV" – "For patients with resting heart rate ≥70, on maximally tolerated beta-blocker dose in sinus rhythm, NYHA class II-III" – "For high-risk patients already on optimal GDMT with worsening HF as evidenced by a HF hospitalization or requirement for intravenous diuretics" • Four action nodes (diamonds, left to right): – "Diuretic agent (Figure 3F)" – "Hydralazine + isosorbide dinitrate (Figure 3G)" – "Ivabradine (Figure 3H)" – "Vericiguat (Figure 3I)" # Connectors : • Downward arrows from "HFrEF Stage C Treatment" to "ARNI* + evidence-based beta-blocker† + mineralocorticoid antagonist + SGLT inhibitor" • Four downward arrows from main therapy node to each decision node • Each decision node connects downward to its respective action node: – "Titrate" arrow to "Diuretic agent" – "Add" arrow to "Hydralazine + isosorbide dinitrate" – "Add" arrow to "Ivabradine" – "Add" arrow to "Vericiguat" # Layout : • Vertical flow from top to bottom • After main therapy, splits into four parallel branches, each with a decision node and corresponding action node • Colour coding: main therapy node (green diamond), decision nodes (orange rectangles), action nodes (green or orange diamonds), connectors (black arrows) # Analysis : • The flowchart emphasizes a foundational quadruple therapy for all HFrEF Stage C patients, then stratifies further medication choices based on specific clinical scenarios (volume overload, persistent symptoms in African-American patients, elevated heart rate, or high-risk status). • Each branch provides a clear escalation or addition of therapy tailored to patient phenotype, supporting individualized care. • The structure allows for rapid identification of next steps in management depending on patient response and risk factors.

This Comparison Chart displays two side-by-side antero-posterior (AP) chest X-rays of an infant, demonstrating the radiographic progression of congestive heart failure management. Panel A (pre-therapy) shows significant cardiomegaly with an increased cardiothoracic ratio and prominence of the left heart border. The lung fields exhibit increased perihilar opacities and blurred vascular markings, characteristic of pulmonary venous congestion. Panel B (post-therapy, following hydralazine administration) demonstrates a remarkable improvement in the clinical state. There is a visible reduction in the heart silhouette size, suggesting a decrease in moderate cardiomegaly. The lungs appear significantly clearer with increased radiolucency and sharper definition of vascular markings and rib outlines, indicating the resolution of pulmonary venous congestion. These diagnostic images are essential for teaching pediatric cardiology concepts, specifically the radiographic manifestations of left ventricular dysfunction and the effectiveness of vasodilator therapy in improving cardiac output and reducing pulmonary backup in infants.

A multi-panel medical image illustrating the clinical presentation and surgical management of congenital heart disease in a pediatric patient with Trisomy 21 (Down Syndrome). Panel (a) is a clinical photograph of a child displaying characteristic dysmorphic facial features, including upward slanting palpebral fissures, a flat nasal bridge, and a protruding tongue. Panels (b), (c), and (d) provide intraoperative views during a median sternotomy. Panel (b) shows the exposed heart before surgical repair, identifying a ventricular septal defect (VSD) and a glutaraldehyde-treated pericardial patch (P) ready for use. Panel (c) demonstrates the intraoperative site after the VSD has been successfully closed with the patch (marked X). Panel (d) displays the ligation of a patent ductus arteriosus (PDA). The surgical images are labeled from the 'Surgeon's View' with 'Head End' and 'Foot End' orientations provided. This composite image serves to correlate the phenotypic features of Trisomy 21 with common associated cardiac anomalies (VSD and PDA) and their definitive surgical correction.

(Continued) <table><thead><tr><th colspan="2">Topic 12: A Management of the Transition from Pediatric to Adult Care After Heart Transplantation</th></tr><tr><th>2010 Prior Guideline Recommendation</th><th>2023 Guideline Update Recommendation</th></tr></thead><tbody><tr><td>of symptoms and signs requiring immediate medical attention and understanding of health care coverage and eligibility requirements).<br>Class I, Level of Evidence: C.</td><td></td></tr><tr><td>Health care providers should prepare the parents for the transition from pediatric to adult care by encouraging independence and self-responsibility in the child.<br>Class I, Level of Evidence: C.</td><td>Continuing approval without change.</td></tr><tr><td>Practitioners who care for adults should cultivate partnerships with their pediatric colleagues to gain insight into the care of adolescents and the impact of childhood chronic disease on development and management of childhood causes of end-stage organ failure and congenital diseases. Ideal adult site resources also include a dedicated transfer liaison nurse coordinator, a social worker, and a reproductive specialist.<br>Class I, Level of Evidence: C.</td><td>Continuing approval without change.</td></tr><tr><td>New recommendation</td><td>Pediatric transplant care providers should prepare the patient for transition from pediatric care to adult care by encouraging a move toward independence demonstrated by taking on self-care responsibilities and involvement in decision-making.<br>Class I, Level of Evidence: C</td></tr><tr><td>New recommendation</td><td>Structured transition program for adolescent heart transplant recipients should be adopted by pediatric heart transplant centers to increase knowledge and decrease non-adherence.<br>Class I, Level of Evidence: C</td></tr><tr><td>New recommendation</td><td>A transition education preparation should begin from age 12 and continue into the early twenties.<br>Class I, Level of Evidence: C</td></tr><tr><td>New recommendation</td><td>The following resources should be considered and used to aid in care transitions. Evolving development of these resources may lead to limited availability in some areas.<br>• Tailored solutions to help adolescents take their medications should be explored. Technology such as smart phones can help prepare adolescents through apps, for example setting alarms to avoid forgetfulness, but given that nonadherence is a multi-faceted problem, several options should be considered taking the adolescent's preferences into account.<br>• The American College of Cardiology has produced a transition of care tool kit, which can be adapted to the practice patterns of international transplant centers. This includes a transition readiness self-assessment (which allows health care providers to assess an adolescent's likelihood for successful transition), knowledge assessments, clinical summaries, and emergency care plans that young people can keep and share with adult providers.<br>• Health care providers should consider developing clinic times or waiting room options more inviting for pediatric patients transitioning to adult care. A clinic option for patients from 12 years old to early adulthood has been shown to increase overall patient satisfaction and should be considered when feasible.<br>Class I, Level of Evidence: C</td></tr></tbody></table>

This composite figure illustrates advanced interventional and surgical management of pediatric pulmonary hypertension and heart failure through a four-panel multimodal display. Panels A and B are fluoroscopic angiograms showing a surgical reversed 'Potts' shunt (a connection between the descending aorta and the left pulmonary artery). Panel A demonstrates the initial 6mm PTFE shunt, while Panel B shows the same shunt dilated using an 8mm Formula stent, with a guidewire visible indicating the percutaneous procedure. Panel C is an MRI scan in the axial plane showing bilateral pulmonary artery banding, characterized by physical constrictions on both pulmonary arteries to balance circulation. Panel D presents a Doppler echocardiography trace with a spectral display demonstrating bidirectional flow dynamics: a systolic right-to-left shunt and a diastolic left-to-right shunt. The images collectively demonstrate the clinical challenge of maintaining a parallel fetal-like circulation and the physiological hemodynamics resulting from surgical and transcatheter interventions in complex congenital heart disease cases.

This diagnostic image is a posterior-anterior (PA) chest radiograph of a pediatric patient demonstrating severe pathology. The most prominent finding is massive cardiomegaly, with the cardiac silhouette occupying a significantly increased cardiothoracic ratio, nearly filling the lower half of the thoracic cavity. This global enlargement is consistent with advanced congenital heart disease, such as Ebstein's anomaly. Additionally, the bilateral hilar regions exhibit increased vascular density and indistinctness, characteristic of pulmonary hilar congestion and venous hypertension. The lung fields show prominent vascular markings extending from the hila, though the peripheral lung zones remain relatively clear. The bony structures, including the ribs and clavicles, appear developmentally appropriate for a child. This radiograph serves as a critical educational example of extreme cardiac remodeling and secondary pulmonary vascular changes resulting from chronic volume overload and right-sided heart failure.